354 related articles for article (PubMed ID: 23737688)
1. Axillary lymph node status, adjusted for pathologic complete response in breast and axilla after neoadjuvant chemotherapy, predicts differential disease-free survival in breast cancer.
Zhang GC; Zhang YF; Xu FP; Qian XK; Guo ZB; Ren CY; Yao M
Curr Oncol; 2013 Jun; 20(3):e180-92. PubMed ID: 23737688
[TBL] [Abstract][Full Text] [Related]
2. Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases.
van Nijnatten TJ; Simons JM; Moossdorff M; de Munck L; Lobbes MB; van der Pol CC; Koppert LB; Luiten EJ; Smidt ML
Breast Cancer Res Treat; 2017 May; 163(1):159-166. PubMed ID: 28213782
[TBL] [Abstract][Full Text] [Related]
3. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.
Rusthoven CG; Rabinovitch RA; Jones BL; Koshy M; Amini A; Yeh N; Jackson MW; Fisher CM
Ann Oncol; 2016 May; 27(5):818-27. PubMed ID: 26861597
[TBL] [Abstract][Full Text] [Related]
4. Is Pathologic Axillary Staging Valid If Lymph Nodes Are Less than 10 with Axillary Lymph Node Dissection after Neoadjuvant Chemotherapy?
Choi HJ; Ryu JM; Lee JH; Bang Y; Oh J; Chae BJ; Nam SJ; Kim SW; Lee JE; Lee SK; Yu J
J Clin Med; 2022 Nov; 11(21):. PubMed ID: 36362792
[TBL] [Abstract][Full Text] [Related]
5. Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?
Garcia-Tejedor A; Fernandez-Gonzalez S; Ortega R; Gil-Gil M; Perez-Montero H; Fernandez-Montolí E; Stradella A; Recalde S; Soler T; Petit A; Bajen MT; Benitez A; Guma A; Campos M; Pla MJ; Martinez E; Laplana M; Pernas S; Perez-Sildekova D; Catala I; Ponce J; Falo C
Breast Cancer Res Treat; 2021 Feb; 185(3):657-666. PubMed ID: 33068198
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
[TBL] [Abstract][Full Text] [Related]
7. Neo-adjuvant chemotherapy and axillary de-escalation management for patients with clinically node-negative breast cancer.
Shi ZQ; Qiu PF; Liu YB; Cong BB; Zhao T; Chen P; Wang CJ; Zhang ZP; Sun X; Wang YS
Breast J; 2019 Nov; 25(6):1154-1159. PubMed ID: 31332886
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of pathological nodal burden after neoadjuvant chemotherapy in initially cN0-1 breast cancer patients: a dual-center, 10-year survival analysis.
Maimaitiaili A; Fan Z; Zhang J; Wang Y; Shi B; Zheng J; Li G; Zhao Y; Pu S; He J; Qu F; Zhang H
Ther Adv Med Oncol; 2024; 16():17588359241248318. PubMed ID: 38716480
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors for omitting lymphadenectomy in patients with node-positive breast cancer treated with neo-adjuvant systemic therapy.
Fernandez-Gonzalez S; Falo C; Pla MJ; Verdaguer P; Nuñez D; Guma A; Soler T; Vethencourt A; Vázquez S; Fernandez-Montoli ME; Campos M; Pernas S; Gil M; Ponce J; Garcia-Tejedor A
Breast J; 2020 May; 26(5):888-896. PubMed ID: 32052521
[TBL] [Abstract][Full Text] [Related]
10. Association of Tumor Molecular Subtype and Stage with Breast and Axillary Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer.
Myers SP; Ahrendt GM; Lee JS; Steiman JG; Soran A; Johnson RR; McAuliffe PF; Diego EJ
Ann Surg Oncol; 2021 Dec; 28(13):8636-8642. PubMed ID: 34142288
[TBL] [Abstract][Full Text] [Related]
11. Axillary response and outcome in breast cancer patients after neoadjuvant treatment: The role of radiotherapy in reducing recurrence in ypN0 patients with initially cN+ stage.
Ren X; Yu Y; Liu L; Xia W; Ni R; Wei S; Wu J; Wei Q
Front Oncol; 2023; 13():1093155. PubMed ID: 37077821
[TBL] [Abstract][Full Text] [Related]
12. Role of Elective Nodal Irradiation in Patients With ypN0 After Neoadjuvant Chemotherapy Followed by Breast-Conserving Surgery (KROG 16-16).
Cho WK; Park W; Choi DH; Kim YB; Kim JH; Kim SS; Kim K; Kim JH; Ahn SJ; Lee SY; Lee J; Kim SW; Kwon J; Ahn KJ
Clin Breast Cancer; 2019 Feb; 19(1):78-86. PubMed ID: 30241965
[TBL] [Abstract][Full Text] [Related]
13. Update on sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patient.
Franceschini G; Di Leone A; Sanchez AM; D'Archi S; Terribile D; Magno S; Scardina L; Masetti R
Ann Ital Chir; 2020; 91():465-468. PubMed ID: 32312945
[TBL] [Abstract][Full Text] [Related]
14. Sentinel Lymph Node Biopsy in Breast Cancer Patients With Pathological Complete Response in the Axillary Lymph Node After Neoadjuvant Chemotherapy.
Kim H; Han J; Kim SY; Lee ES; Kang HS; Lee S; Jung SY; Lee E
J Breast Cancer; 2021 Dec; 24(6):531-541. PubMed ID: 34979599
[TBL] [Abstract][Full Text] [Related]
15. Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.
Fowble B; Jairam AK; Wang F; Peled A; Alvarado M; Ewing C; Esserman L; Park C; Lazar A
Clin Breast Cancer; 2018 Feb; 18(1):e107-e113. PubMed ID: 28830795
[TBL] [Abstract][Full Text] [Related]
16. Axillary pathologic response after neoadjuvant chemotherapy and surgery according to breast cancers subtypes and survival impact.
Jankowski C; Michel E; Vincent L; Beltjens F; Arnould L; Ladoire S; Coutant C
Bull Cancer; 2023 Jun; 110(6):605-615. PubMed ID: 37080848
[TBL] [Abstract][Full Text] [Related]
17. Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer.
Tsai J; Bertoni D; Hernandez-Boussard T; Telli ML; Wapnir IL
Ann Surg Oncol; 2016 Oct; 23(10):3310-6. PubMed ID: 27401442
[TBL] [Abstract][Full Text] [Related]
18. Number of negative lymph nodes as a prognostic factor for ypN0-N1 breast cancer patients undergoing neoadjuvant chemotherapy.
Xin F; Yu Y; Yang ZJ; Hou LK; Mao JF; Xia L; Wang X; Cao XC
Tumour Biol; 2016 Jun; 37(6):8445-54. PubMed ID: 26733172
[TBL] [Abstract][Full Text] [Related]
19. Axillary Lymph Node Ultrasound Following Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: Results from the SN FNAC Study.
Morency D; Dumitra S; Parvez E; Martel K; Basik M; Robidoux A; Poirier B; Holloway CMB; Gaboury L; Sideris L; Meterissian S; Boileau JF
Ann Surg Oncol; 2019 Dec; 26(13):4337-4345. PubMed ID: 31605348
[TBL] [Abstract][Full Text] [Related]
20. [Impact of stages of axillary lymph nodes and pathological response to neoadjuvant chemotherapy on the survival of breast cancer patients].
Wang W; Zhang B; Xu X; Wang X; Zhang P; Wang X
Zhonghua Zhong Liu Za Zhi; 2015 Mar; 37(3):195-9. PubMed ID: 25975788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]